

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
4202.01 US

In Re Application: Jonathan L. Sessler et al.

DEC 13 2002

Serial No.
699,027

Filing Date
10/27/2000

Examiner
Lukton, David

Group Art Unit
1653

**METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS,
AND OTHER NEOPLASTIC TISSUE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 16-1450 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F //)

////

(Date)

Signature

////

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited December 9, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Rhonda J. Stine

Signature of Person Mailing Correspondence

Rhonda J. Stine

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Vinit G. Kathardekar

Signature

Dated: December 9, 2002

Vinit G. Kathardekar, Reg. 39,461
Pharmacyclics, Inc.
995 E. Arques Avenue
Sunnyvale, California 94085
Phone: 408.774.0330
Fax: 408.774.0340
Email: Legal@pcyc.com

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
4202.01 US

In Re Application **Jonathan L. Sessler et al.**

Serial No.

Filing Date

Examiner

Group Art Unit

10/27/2000

Lukton, David

1653

Title:

**METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS,
AND OTHER NEOPLASTIC TISSUE**

Address to:


Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).



RECEIVED
DEC 16 2002
TECH CENTER 1600/2900